According to data and analytics company, GlobalData, new real-world evidence will support the use of a biosimilar treatment for Crohn’s disease (CD), leading to a boost in the biosimilar market value.
A recent report from CPhI Japan has forecast that this year, 2018, will be a transformative year for Japanese pharma as the market is expected to see growth in generics, biosimilars and internationalisation.
Dr Hani El-Sabbahy, a biopharmaceutical application engineering specialist at science-based technology company 3M, outlines some of the challenges associated with continuous multicolumn protein A chromatography.
Harriet Lewis, ABPI's Medicines Optimisation Lead, discusses the future of biosimilars in the UK asking the pertinent question: will they revolutionise healthcare?
Here, Michael Merges, Catalent Biologics, and Brian Fahie, Biogen, discuss the growing need for partners who can provide niche technologies to accelerate development projects.
In this article Robert L. Moore, PhD, from Cryoport Services discusses the key considerations of manufacturing biologics in a commercial environment and the benefits of intelligent logistics.
In this article Steve Lam, senior vice president and head of biologics, Patheon, looks at which choice is best when developing a biomanufacturing strategy.
Global pharmaceutical and biopharmaceutical open access capability platform, WuXi AppTec, has published a report on immunotherapy, identifying that smaller biotech firms and early-stage companies will be the biggest driver behind therapy innovation.
Mark Kelly, 3M Ireland, reflects on some of the challenges facing the biotechnology industry, and explains how the science-based technology company is rising to them.
